Mary Caffrey

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

This article appears in the April issue of Evidence-Based Oncology.

The findings appear as multiple lawsuits pit pharmaceutical companies against hospitals as well as HHS.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and myelodysplastic syndrome (MDS).

Phase 2 results reported at the European Lung Cancer Conference show a favorable signal for overall survival for the first-line treatment of KRAS-mutated non–small cell lung cancer (NSCLC). A phase 3 trial is enrolling now.

The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.

Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.

As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.

A discussion with the presidents of the Association of Cancer Care Centers (ACCC) and the American Society of Clinical Oncology took place at the ACCC 51st Annual Meeting & Cancer Center Business Summit.

Nick Webb tells attendees at the Association of Cancer Care Centers that consumer experience and workforce happiness will be keys to success in the future for health systems.

Posters presented at the Association of Cancer Care Centers (ACCC) opening session covered initiatives to boost clinical trial diversity and address disparities in bladder cancer trials.

The Association of Cancer Care Centers has spent years working for greater diversity in clinical trials. ACCC members will bring concerns to Congress ahead of their annual business meeting in Washington, DC.

Jay T. Rubinstein, MD, PhD, University of Washington School of Medicine, discusses DB-OTO, an investigational gene therapy with potential to treat otoferlin gene–related hearing loss.

Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell carcinoma (RCC).

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.

Presentations at the session on antibody drug conjugates covered targeting HER2 and novel combinations.

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).

City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.

The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in prostate cancer.

Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic castration-resistant prostate cancer (mCRPC).